BRISBANE, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA ), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that, as an inducement material to entering into employment with CareDx, on October 27, 2017, eight new employees were awarded grants of options to purchase CareDx common stock under NASDAQ Listing Rule 5635(c)(4). The option grants entitle the employees to purchase, in the aggregate, up to 29,900 shares of common stock under the CareDx 2016 Inducement Equity Incentive Plan at an exercise price per share of $5.90, the closing price per share of CareDx’s common stock as reported on the Nasdaq Global Market on October 27, 2017, the date of grant. Each of the stock options is an incentive stock option that vests 1/4th on the one year anniversary of the date of commencement of the employee’s employment with CareDx and 1/48th per month thereafter for the 36 immediately following months, assuming in each case the employee remains continuously employed by CareDx as of such date.
CareDx is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About CareDx CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com .
CONTACTS:
CareDx, Inc. Sasha King Chief Commercial Officer 415-287-2393 sking@caredx.com
Investor Relations David Clair Integrated Corporate Relations, Inc. 646-277-1266 david.clair@icrinc.com
